EUVIMEDEUVIMED entdecken
Crossref

Life Expectancy in High‐Grade Incidental Prostate Cancer Patients Versus Population‐Based Controls According to Treatment Type

Francesco Di Bello iD, Letizia Maria Ippolita Jannello, Andrea Baudo, Mario de Angelis, Carolin Siech iD, Zhe Tian, Jordan A Goyal, Massimiliano Creta, Gianluigi Califano, Giuseppe Celentano, Pietro Acquati, Fred Saad und 7 weitere

The Prostate · 2025

DOI: 10.1002/pros.24816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Francesco Di Bello und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Life Expectancy, Neoplasm Grading, SEER Program. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To quantify the differences in 5‐year overall survival (OS) between high‐grade (Gleason sum 8–10) incidental prostate cancer (IPCa) patients and age‐matched male population‐based controls, according to treatment type: no active versus active treatment. Materials and Methods We relied on the Surveillance, Epidemiology, and End Results (SEER) database (2004–2015) to identify not actively treated and actively treated high‐grade IPCa patients. For each case, we simulated an age‐matched male control (Monte Carlo simulation), relying on Social Security Administration Life Tables (2004–2020) with 5 years of follow‐up. Additionally, we relied on Kaplan–Meier plots to display OS for each treatment type. Multivariable Cox regression models were fitted to predict overall mortality (OM).

Results

Of 564 high‐grade IPCa patients, 345 (61%) were not actively treated versus 219 (39%) were actively treated, either with radical prostatectomy or radiotherapy. Median OS was 3 years for not actively treated high‐grade IPCa patients, with OS difference at 5 years follow‐up of 27% relative to their age‐matched male population‐based controls (37% vs. 64%). Median OS was 8 years for actively treated high‐grade IPCa patients, with OS difference at 5 years follow‐up of 6% relative to their age‐matched male population‐based controls (68% vs. 74%). In the multivariable Cox regression model, active treatment independently predicted lower OM (hazard ratio = 0.6; 95% confidence interval = 0.4–0.8; p < 0.001).

Conclusion

Relative to Life Tables' derived age‐matched male controls, not actively treated high‐grade IPCa patients exhibit drastically worse OS than their actively treated counterparts. These observations may encourage clinicians to consider active treatment in newly diagnosed high‐grade IPCa patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsLife ExpectancyNeoplasm GradingSEER ProgramProstatectomyHumansMaleAgedMiddle AgedCase-Control StudiesIncidental Findings

Stichwörter der Autor:innen

Gleason scoreSEERTURPactive surveillancesurvival

Autor:innen und Institutionen

  • Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
  • Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Department of Urology Unit, Università degli Studi di Milano, Milan, Italy.
  • Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.
  • Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

ORCID-Profile: Francesco Di Bello, Carolin Siech

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Di Bello, F., Jannello, L. M. I., Baudo, A., de Angelis, M., Siech, C., Tian, Z., Goyal, J. A., Creta, M., Califano, G., Celentano, G., Acquati, P., Saad, F., Shariat, S. F., Carmignani, L., de Cobelli, O., Briganti, A., Chun, F. K. H., Longo, N., & Karakiewicz, P. I. (2025). Life Expectancy in High‐Grade Incidental Prostate Cancer Patients Versus Population‐Based Controls According to Treatment Type. The Prostate. https://doi.org/10.1002/pros.24816

Vancouver

Di Bello F, Jannello LMI, Baudo A, de Angelis M, Siech C, Tian Z, et al. Life Expectancy in High‐Grade Incidental Prostate Cancer Patients Versus Population‐Based Controls According to Treatment Type. The Prostate. 2025. doi:10.1002/pros.24816

BibTeX
@article{DiBello2025,
  author = {Di Bello, Francesco and Jannello, Letizia Maria Ippolita and Baudo, Andrea and de Angelis, Mario and Siech, Carolin and Tian, Zhe and Goyal, Jordan A and Creta, Massimiliano and Califano, Gianluigi and Celentano, Giuseppe and Acquati, Pietro and Saad, Fred and Shariat, Shahrokh F and Carmignani, Luca and de Cobelli, Ottavio and Briganti, Alberto and Chun, Felix K H and Longo, Nicola and Karakiewicz, Pierre I},
  title = {Life Expectancy in High‐Grade Incidental Prostate Cancer Patients Versus Population‐Based Controls According to Treatment Type},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24816}
}
Kostenlos starten →